

F.No.20 (8)/2013/Div-III/NPPA/Part-II
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

3rd & 5th Floor,
YMCA Culture Centre Building,
No. 1, Jai Singh Road, New Delhi-110001

Date: 2nd May, 2017

OFFICE MEMORANDUM

Sub: Compliance of price fixation of coronary stents and related issues.

The undersigned is directed to state that, vide Gazette Notification S.O. No. 412 (E), dated 13.02.2017 National Pharmaceutical Pricing Authority (NPPA) has notified the ceiling prices of coronary stents. Attention is also drawn to subsequent clarifications issued vide following Office Memoranda:

Sl no	Date	Subject
1	16-02-2017	Implementation of prices fixed and notified for Coronary Stents under the provision of DPCO,2013 – reg.
2	20-02-2017	Clarification on trade margins in respect of coronary stents
3	21-02-2017	Monitoring/Implementation of Coronary Stents Ceiling Prices fixed and notified under the provision.
4	23-02-2017	Compliance and enforcement of coronary stent price cap notification No 8(41)/2017/DP/NPPA/Div II dated 13-Feb-2017.
5	28-02-2017	Monitoring/Implementation of Coronary Stents ceiling prices fixed and notified under the provisions of Drug Prices Control Order, 2013 (DPCO, 2013)-reg.
6	02-03-2017	Non-compliance of Stent price gazette notification indicating details of Stents in the bills by the Hospitals.
7	13-04-2017	Compliance of price fixation of coronary stents and related issues.
8	20-04-2017	Compliance of price fixation of coronary stents and related issues
9	28-04-2017	Ensuring compliance of the price capping of the coronary stents along with maintaining its uninterrupted supply – regarding.

2. As per the notification and clarificatory office memoranda issued, all manufacturers/importers/marketers of coronary stents and the hospitals are required to comply with the notified ceiling price of stents and to adhere to all the instructions issued so far in letter and spirit.

3. All manufactures/importers are under legal obligation to maintain smooth production and supply of coronary stents of all brands which were available in the country before price cap. The companies manufacturing coronary stents in India have also been directed to maintain production/import/supply of coronary stents.

4. All hospitals, doctors and patients are hereby informed that if there is any shortage of the following specified stents viz., Resolute Onyx Zotarolimus Eluting Coronary Stent System (M/s India Medtronic Pvt. Ltd.), Absorb GTI-Bioresorbable Vascular Scaffold (BVS), (M/s

Abbott Healthcare Pvt. Ltd.), 'Xience Alpine Medical Device [cardiac stent], (M/s Abbott Healthcare Pvt. Ltd.), SYNERGY™ monorail Everolimus-Eluting Platinum Chromium Coronary Stent System with Biodegradable polymer, Promus PREMIER™ Everolimus- Eluting Coronary Stent System (M/s Boston Scientific India Private Limited), they are requested to inform National Pharmaceutical Pricing Authority(NPPA) immediately about such shortage through any one of the following means:

- i. Call NPPA's toll free helpline number 1800111255
 - ii. Lodge a complaint through grievance redressal system "**PHARMA JAN SAMADHAN**" by visiting the website of NPPA at www.nppaindia.nic.in and
 - iii. Message the complaint through WhatsApp on mobile number 9958217773
5. Immediately after the receipt of the complaint, NPPA will initiate action on priority basis to ensure the availability of stents at places where the shortage was reported.
6. All SDCs are hereby requested to carryout checks to ensure that the following specified stents viz., Resolute Onyx Zotarolimus Eluting Coronary Stent System, Absorb GTI-Bioresorbable Vascular Scaffold (BVS), Xience Alpine Medical Device [cardiac stent], SYNERGY™ monorail Everolimus-Eluting Platinum Chromium Coronary Stent System with Biodegradable polymer, Promus PREMIER™ Everolimus- Eluting Coronary Stent System are available in hospitals and with distributors. If required necessary inspections should be carried at place of business of stent companies/distributors/hospitals under para 30 of DPCO, 2013 and take necessary action. A report in this regard may be sent to NPPA subsequently.



(Kalyan Nag)
Adviser

Email: adv-pricing.nppa@nic.in

To:

1. All Cardiac Stents manufacturers and importers and respective associations
2. All State Drug Controllers
3. All hospital associations/Cardiological Society of India/IMA/MCI
4. General Public